Assessment of outcome in clinical trials in mild Alzheimer�s disease: Urgent time for a rethink?

Morrison, Yvonne; Wilson, J. T. L.; Kelly, Fiona; Bennett, C.N.; Duffy, Fiona; McGoldrick, Susan; Reynish, Emma

doi:10.13172/2054-734x-1-1-921

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since optimal results of the administration of antioxidants may be expected in early or even presymptomatic stages of AD, the diagnostic identification of subtle neuropathological alterations and biomarkers related to the disease process are required. Furthermore, the tools currently used to assess outcomes may not be able to detect minimal changes in cognitive functions in early stages of AD (Morrison et al, 2013).…”

Section: Future Directionsmentioning

confidence: 99%

Editorial

Shahidi¹

2020

Journal of Food Bioactives

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by globally impaired cognitive functions. Oxidative stress is involved in the formation of plaques and tangles, which damage neuronal cells in AD. Treatments retarding the progression of AD or significantly improving cognition are not available. Diet has been recognized as a modifiable lifestyle factor capable of affecting the risk of developing AD, since it may influence inflammation and oxidative stress in the brain. Dietary intake of natural antioxidants, such as polyphenols, carotenoids and vitamins C and E, is thought to reduce oxidative stress and to have preventive or therapeutic potential in AD. Several antioxidants have shown promise in animal models of AD. However, there is no evidence of clinical efficacy of natural antioxidants in people with AD. The use of antioxidants may be hindered by their limited bioavailability. Furthermore, antioxidants administered in high concentrations could have detrimental effects due to their capacity to act as prooxidants. Potential effects of natural antioxidants in the prevention of AD should be assessed in studies with long-term exposure to compounds with high bioavailability. In addition, the assessment of the effectiveness of antioxidant-rich diets in AD deserves further investigation.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Editorial

Shahidi¹

2020

Journal of Food Bioactives

View full text Add to dashboard Cite

show abstract

Medical foods in Alzheimer’s disease

Lange

Guo

Kanaya

et al. 2019

Food Science and Human Wellness

View full text Add to dashboard Cite

Do natural antioxidants play a role in Alzheimer's disease?

Lange¹,

Lange²,

Nakamura³

et al. 2020

Journal of Food Bioactives

View full text Add to dashboard Cite

SARS CoV-2 virus is primed by proteases before it attaches to host cells and causes the Coronavirus Diseases-2019 (COVID-19). The proteases that activate SARS-CoV-2 virus can be inhibited by proteins naturally occurring in human plant foods such as legumes. Food science contribution to the fight against SARS-CoV-2 infection and COVID-19 needs to extend beyond the traditional involvement in developing and securing high quality foods to include investigating foods rich in plant protease inhibitors as novel foods for SARS-CoV-2 and COVID-19 prevention.

show abstract

Assessment of outcome in clinical trials in mild Alzheimer�s disease: Urgent time for a rethink?

Cited by 3 publications

References 16 publications

Editorial

Editorial

Medical foods in Alzheimer’s disease

Do natural antioxidants play a role in Alzheimer's disease?

Contact Info

Product

Resources

About